The investigations center on concerns that insiders may reap financial benefits unavailable to common shareholders, or that deal terms could inadvertently stifle superior competing offers. For Supernus Pharmaceuticals (SUPN), the proposed sale to Indivior involves a stock-for-stock exchange of 1.5401 Indivior shares per Supernus share. Meanwhile, the cash-based acquisitions include Integer Holdings (ITGR) at $127.00 per share and Atkore Inc. (ATKR) at $95.00 per share.
The inquiry into Lantheus Holdings (LNTH) involves a $102.50 per share cash price, supplemented by non-transferable Contingent Value Rights worth up to $12.00, contingent upon specific commercial milestones through 2030. Halper Sadeh LLC, led by attorneys Daniel Sadeh and Zachary Halper, aims to seek increased consideration or additional disclosures for investors. The firm operates on a contingent fee basis for these matters, noting that past corporate reforms and recoveries do not guarantee similar outcomes in these current proceedings.
Comments (0)
No comments yet. Be the first!